Related Experiment Videos
Four-year experience with a recombinant hepatitis B vaccine
W Jilg1, M Schmidt, F Deinhardt
1Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of Munich.
Infection
|March 1, 1989
Summary
Recombinant hepatitis B vaccination is highly effective, with 99.1% of healthy adults producing protective antibodies. Antibody levels decline over time, but revaccination effectively restores immunity, showing no difference from plasma-derived vaccines.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Hepatitis B remains a significant global health concern.
- Effective vaccination strategies are crucial for disease prevention.
- Recombinant vaccines offer a safe and scalable alternative to plasma-derived vaccines.
Purpose of the Study:
- To evaluate the immunogenicity and safety of a recombinant hepatitis B vaccine.
- To assess the persistence of anti-HBs antibodies post-vaccination.
- To compare the efficacy of recombinant and plasma-derived vaccines.
Main Methods:
- Healthy adults received five lots of recombinant hepatitis B vaccine.
- Antibody levels (anti-HBs) were measured post-vaccination.
- Antibody persistence was monitored for up to 4 years.
- Revaccination responses were assessed in individuals with low antibody levels.
Main Results:
- 99.1% of participants developed antibodies against hepatitis B surface antigen (anti-HBs).
- Higher peak anti-HBs concentrations were observed in females and younger individuals.
- Antibody levels declined over time, with 21.7% and 32.3% falling below protective levels after 3 and 4 years, respectively.
- Revaccination promptly restored protective antibody levels.
- No substantial differences were found between recombinant and plasma-derived vaccines.
Conclusions:
- The recombinant hepatitis B vaccine is immunogenic and well-tolerated.
- Antibody persistence is influenced by peak antibody levels and declines over several years.
- Revaccination is effective in individuals with waning immunity.
- Recombinant and plasma-derived vaccines demonstrate comparable efficacy.